Dehydroepiandrosterone (DHEA) and the menopause: an update.
Since we last reviewed this topic in 2001, considerably more information about dehydroepiandrosterone (DHEA) has accrued, but this has not necessarily left us any wiser about the use of this steroid in postmenopausal women. There is no further evidence that DHEA supplementation is likely to be useful in the prevention of cardiovascular disease or cognitive impairment, or in the promotion of wellbeing. Evidence has, however, accumulated for beneficial effects of DHEA on osteoporosis, both in postmenopausal women and in patients receiving long-term glucocorticoid therapy. What is also emerging is a link between low DHEA levels and cardiovascular risk, and between high DHEA levels and breast cancer risk. In fact, the benefits and adverse effects of DHEA administration in postmenopausal women increasingly resemble those of conventional hormone replacement therapy. Overall, we conclude that DHEA is not currently to be recommended for therapeutic use in the majority of postmenopausal women. However, DHEA supplementation may be of benefit in two specific groups of women: those with the lowest circulating levels of DHEA; and those for whom osteoporosis is a particular problem.
Raven
P W
PW
Metabolic and Clinical Trials Unit, Royal Free and University College Medical School, University College London, London, UK.
Hinson
J P
JP
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000139:chemically induced; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003072:Cognition Disorders / Q000517:prevention & control; D003687:Dehydroepiandrosterone / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D017698:Postmenopause / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016387:Women's Health
D000276:Adjuvants, Immunologic; D003687:Dehydroepiandrosterone